Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Open accessAbstract
BACKGROUND: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not candidates for other anti-cancer therapies, highlighting their need for active treatment options. METHODS: We performed a retrospective analysis of patients from multiple centers with advanced solid tumors and baseline organ dysfunction who received anti-PD-1 therapy. Organ dysfunction was defined as cardiac (left ventricular ejection fraction ≤45 %), renal (creatinine ≥2 mg/dL or GFR ≤30 ml/min) or hepatic dysfunction (evidence of cirrhosis on imaging or AST, ALT or bilirubin ≥3x ULN). We assessed change in organ dysfunction, immune related adverse events (irAEs), response rate, progression free survival (PFS) and overall survival (OS). RESULTS: = 17), hepatic dysfunction (7), cardiac dysfunction (11), including >1 organ dysfunction (8). Worsening organ dysfunction requiring hospitalization or dose delays occurred in 8 patients (30 %) although in most cases this was thought not-drug related and resolved with supportive care. Grade 3 irAEs occurred in 2 pts (7 %; hepatitis and colitis). Thirteen of 27 patients had ongoing treatment benefit (objective response or stable disease) at data collection (48 %). Eleven patients had primary progressive disease (41 %), 11 had stable disease (41 %), 4 had partial responses (15 %), and one had a complete response (4 %). Overall, median PFS was 168 days. Median OS was not reached. CONCLUSIONS: In our experience, anti-PD-1 agents in this group of patients with cardiac, hepatic or renal dysfunction were associated with tolerable irAEs and infrequent manageable worsening of organ dysfunction. Further, objective responses and prolonged PFS were observed in a number of patients. Thus, patients with baseline organ dysfunction may be considered for anti-PD-1 therapy with appropriate clinical monitoring.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several studies suggest thyroid dysfunction is associated with improved overall cancer survival, though the mechanism is not well understood.
“Several studies have suggested that thyroid dysfunction is associated with improved overall survival from a cancer standpoint, although the mechanism for this type of association is not well understood.39,40”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Self-citationNivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · see citing works
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725 · see citing works
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · see citing works
Self-citationTumor Regression and Allograft Rejection after Administration of Anti–PD-1
Lipson, E. J., Bagnasco, S. M., Moore, J. D., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509268 · Cited by 278 · see citing works
Mould, D. R., & Sweeney, K. (2007) · PubMed · Cited by 172 · see citing works
Lipson, E. J., Bodell, M. A., Kraus, E. S., & Sharfman, W. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2314 · Cited by 158 · see citing works
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 145 · see citing works
Plimack, E. R., Joaquim Bellmunt, B., Gupta, S., Berger, R., Montgomery, B., Heath, K., Juco, J. W., Emancipator, K., Pathiraja, K., Lunceford, J. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4502 · Cited by 115 · see citing works
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Morales, R. E., Shoushtari, A. N., Walsh, M. M., Grewal, P., Lipson, E. J., & Carvajal, R. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0066-0 · Cited by 110 · see citing works
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
Davar, D., Wilson, M. A., Pruckner, C., & Kirkwood, J. M. (2015) · Case Reports in Oncological Medicine · doi:10.1155/2015/737389 · Cited by 103 · see citing works
Report of Ipilimumab in a Heart Transplant Patient with Metastatic Melanoma on Tacrolimus
Qin, R., & Salama, A. K. S. (2015) · Melanoma Management · doi:10.2217/mmt.15.27 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
Becker, J. C., Stang, A., DeCaprio, J. A., Cerroni, L., Lebbé, C., Veness, M., & Nghiem, P. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.77 · Cited by 684 · see citing works
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441 · see citing works
Self-citationThe role of exosomal PD-L1 in tumor progression and immunotherapy
Xie, F., Xu, M., Lu, J., Mao, L., & Wang, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1074-3 · Cited by 354 · see citing works
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339 · see citing works
Self-citationChan, S. L., Sun, H., Xu, Y., Zeng, H., El‐Serag, H. B., Lee, J. M., Schwartz, M., Finn, R. S., Seong, J., Wang, X. W., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01042-6 · Cited by 247 · see citing works
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Ellis, S. R., Vierra, A. T., Millsop, J. W., Lacouture, M. E., & Kiuru, M. H. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.105 · Cited by 180 · see citing works
Kambhampati, S., Bauer, K., Bracci, P. M., Keenan, B. P., Behr, S. C., Gordan, J. D., & Kelley, R. K. (2019) · Cancer · doi:10.1002/cncr.32206 · Cited by 104 · see citing works
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118 · see citing works
Self-citationMerkel Cell Carcinoma: Therapeutic Update and Emerging Therapies
Villani, A., Fabbrocini, G., Costa, C., Annunziata, M. C., & Scalvenzi, M. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-0288-z · Cited by 74 · see citing works
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma
Tenold, M. E., Ravi, P. K., Kumar, M., Bowman, I. A., Hammers, H. J., Choueiri, T. K., & Lara, P. N. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279881 · Cited by 70 · see citing works
Parikh, R. B., Min, E. J., Wileyto, E. P., Riaz, F., Gross, C. P., Cohen, R. B., Hubbard, R. A., Long, Q., & Mamtani, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4971 · Cited by 64 · see citing works
Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy
de Almeida, D. V. P., Gomes, J. R., Haddad, F. J., & Buzaid, A. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000217 · Cited by 62 · see citing works
Jeyakumar, N., Etchegaray, M., Henry, J. T., Lelenwa, L. C., Zhao, B., Segura, A., & Buja, L. M. (2020) · Case Reports in Immunology · doi:10.1155/2020/5126717 · Cited by 57 · see citing works
Management of the Adverse Effects of Immune Checkpoint Inhibitors
Morgado, M., Plácido, A. I., Morgado, S., & Roque, F. (2020) · Vaccines · doi:10.3390/vaccines8040575 · Cited by 57 · see citing works
PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
Safi, M., Ahmed, H., Al‐Azab, M., Xia, Y., Shan, X., Alradhi, M., Al-Danakh, A., Shopit, A., & Liu, J. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.09.006 · Cited by 56 · see citing works
Rubio‐Infante, N., Ramírez‐Flores, Y. A., Castillo, E. C., Lozano, O., García‐Rivas, G., & Torre‐Amione, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851032 · Cited by 48 · see citing works
Immunotherapy use outside clinical trial populations: never say never?
Rzeniewicz, K., Larkin, J., Menzies, A. M., & Turajlic, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.199 · Cited by 42 · see citing works
Hsu, C. C.-S., Marshall, J. L., & He, A. R. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0162 · Cited by 41 · see citing works
Siah, K. W., Khozin, S., Wong, C. H., & Lo, A. W. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00046 · Cited by 33 · see citing works
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer
Genova, C., Rossi, G., Rijavec, E., Biello, F., Barletta, G., Tagliamento, M., & Grossi, F. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1313228 · Cited by 36 · see citing works
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023) · Immunological Reviews · doi:10.1111/imr.13249 · Cited by 36 · see citing works
Self-citationSandoval-Sus, J. D., Mogollon-Duffo, F., Patel, A. K., Visweshwar, N., Laber, D. A., Kim, R., & Jagal, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0252-3 · Cited by 34 · see citing works
Immunotherapy Use in Patients With Lung Cancer and Comorbidities
von Itzstein, M. S., Gonugunta, A. S., Mayo, H., Minna, J. D., & Gerber, D. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000484 · Cited by 33 · see citing works
Califano, R., Lal, R., Lewanski, C. R., Nicolson, M. C., Ottensmeier, C. H. H., Popat, S., Hodgson, M. J., & Postmus, P. E. (2018) · Future Oncology · doi:10.2217/fon-2018-0330 · Cited by 30 · see citing works
Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy
Brumbaugh, A. D., Narurkar, R., Parikh, K., Fanucchi, M. P., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000217 · Cited by 26 · see citing works
Management of immune-related adverse events resulting from immune checkpoint blockade
Baroudjian, B., Arangalage, D., Cuzzubbo, S., Hervier, B., Lebbé, C., Lorillon, G., Tazi, A., Zalcman, G., Bouattour, M., Lioté, F., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1562342 · Cited by 28 · see citing works
Ishizuka, S., Sakata, S., Yoshida, C., Takaki, A., Saeki, S., Nakamura, K., & Fujii, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.005 · Cited by 23 · see citing works
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Yang, Y. C., Sun, J., Wu, M., Lau, W. Y., Zheng, S., Wang, X., Chen, X., Fan, J., Dong, J., Cai, J., et al. (2022) · Liver Cancer · doi:10.1159/000526038 · Cited by 21 · see citing works
Hoffman-Censits, J. H., Pal, S. K., Kaiser, C., Ding, B., & Joaquim Bellmunt, B. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000419 · Cited by 20 · see citing works
Assié, J., Corre, R., Levra, M. G., Calvet, C. Y., Gaudin, A.-F., Grumberg, V., Jouaneton, B., Cotté, F.-E., & CHOUAID, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920967237 · Cited by 20 · see citing works
Fretwell, E. C., & Houldsworth, A. (2025) · Journal of Cancer · doi:10.7150/jca.102285 · Cited by 19 · see citing works
Purde, M.-T., Niederer, R., Wagner, N. B., Diem, S., Berner, F., Ali, O. H., Hillmann, D., Bergamin, I., Joerger, M., Risch, M., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03870-6 · Cited by 19 · see citing works
Malaty, M. M., Amarasekera, A. T., Li, C., Scherrer‐Crosbie, M., & Tan, T. C. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13831 · Cited by 19 · see citing works
Huang, Y., Ma, W., Wu, D., Lyu, M., Zheng, Q., Wang, T., Zhou, J., & Liu, C. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-299 · Cited by 18 · see citing works
Chen, J. A., Esteghamat, N., Kim, E. J.-H., García, G., Gong, J., Fakih, M., Bold, R. J., & Cho, M. T. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7328 · Cited by 18 · see citing works
Luo, Y., Zeng, Z., Liu, Y., & Liu, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189008 · Cited by 17 · see citing works
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
NIKE Group, Gallo, M., Guarnotta, V., de Cicco, F., Rubino, M., Faggiano, A., & Colao, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02839-w · Cited by 16 · see citing works
Zhang, Y., He, R. L., Xuan, L., Mao, L., Yin, Z., Zhong, X., Cao, W., Zheng, Q., & Li, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880459 · Cited by 16 · see citing works
The Emerging Role of Tissue-Resident Memory CD8+ T Lymphocytes in Human Digestive Tract Cancers
Mei, X., Li, H., Zhou, X., Cheng, M., & Cui, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.819505 · Cited by 15 · see citing works
Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors.
Zhao, D., Long, X., Fan, H., & Wang, J. (2022) · PubMed Central · Cited by 13 · see citing works
Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Spillane, S., Baxi, S. S., Torres, A. Z., Lenis, D., Freedman, A. N., Mariotto, A. B., & Sharon, E. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0055 · Cited by 12 · see citing works
Sandhu, G., Adattini, J. A., Gordon, E. A., O’Neill, N., Bagnis, C. I., Boddy, A. V., Chambers, P., Flynn, A., Hamilton, B., Ibrahim, K., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103161 · Cited by 11 · see citing works
Self-citationJohns, A. C., Yang, M., Wei, L., Grogan, M. M., Patel, S. H., Li, M., Husain, M., Kendra, K. L., Otterson, G. A., Burkart, J. T., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03371-0 · Cited by 11 · see citing works
Wang, J., Zhang, B., Peng, L., Liu, X., Sun, J., Su, C., Wang, H., Zhao, Z., Si, L., Duan, J., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231187205 · Cited by 11 · see citing works
The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer
Gallego, J. M. M., Juárez, M. H., & Paz-Ares, L. G. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1736554 · Cited by 11 · see citing works
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
Yu, Y., Sun, J., Cai, J., Chen, M., Dai, C., Wen, T., Xia, J., Ying, M., Zhang, Z., Zhang, X., et al. (2024) · Liver Cancer · doi:10.1159/000541622 · Cited by 12 · see citing works
Tanrıverdi, Ö., Ates, S., Sandal, K. K., Uylaş, S., Bosna, İ. Ç., & Alkan, A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220909422 · Cited by 10 · see citing works
Normand, C., Zender, H. O., Staehli, D. M., Chouiter-Djebaili, A. F., & John, G. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220980813 · Cited by 10 · see citing works
Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients
Escoín, C., Blasco, S., & Juan, Ó. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.026 · Cited by 10 · see citing works
Pyoluteorin Induces Apoptosis and Autophagy in NSCLC Cells
Fan, D., Yu, S., Yang, Y., & Qu, S. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00120 · Cited by 9 · see citing works
Abraham, G., Noronha, V., Rajappa, S. J., Agarwal, A., Batra, U., Somani, N., Raja, T., Patil, S., Kaushal, A. M., Joshi, A., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33868 · Cited by 9 · see citing works
Ito, A., Hisano, M., Takahashi, M., Komine, N., Abe, T., & Obara, W. (2019) · Urology Case Reports · doi:10.1016/j.eucr.2019.101048 · Cited by 9 · see citing works
Toxicities and outcomes: Do steroids matter?
Johnson, D. B. (2018) · Cancer · doi:10.1002/cncr.31627 · Cited by 8 · see citing works
Self-citationVatnikov, Y. A., Rudenko, A. A., Gnezdilova, L. A., Sotnikova, E. D., Михайловна, Б. В., Piven, E. A., Kulikov, E. V., Petrov, A., Drukovsky, S. G., & Petrukhina, O. A. (2022) · Veterinary World · doi:10.14202/vetworld.2022.2259-2268 · Cited by 7 · see citing works
Safi, M., Kanesvaran, R., Alradhi, M., Al-Danakh, A., Ping, F., Al-Sabai, N., Shan, X., & Liu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572380 · Cited by 6 · see citing works
Wang, D. Y., Gilbert, J., & Kim, Y. J. (2017) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2017.04.006 · Cited by 5 · see citing works
Kesireddy, M., Marr, A., Schissel, M. E., & Ganti, A. K. (2023) · Cancer · doi:10.1002/cncr.34958 · Cited by 4 · see citing works
Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study
Haeuser, L., Marchese, M., Cone, E. B., Noldus, J., Bayliss, G. P., Kilbridge, K. L., & Trinh, Q. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab187 · Cited by 4 · see citing works
Tascón, J., Casanova, A. G., Vicente-Vicente, L., López-Hernández, F. J., & Morales, A. I. (2025) · Biomedicines · doi:10.3390/biomedicines13030711 · Cited by 4 · see citing works
Odani, K., Tachibana, M., Nogaki, F., & Tsutsumi, Y. (2021) · Clinical Case Reports · doi:10.1002/ccr3.3903 · Cited by 4 · see citing works
Fang, J., & Chen, Z. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/1388517 · Cited by 4 · see citing works
Shaforostova, I., Huss, S., Gerwing, M., Evers, G., & Bleckmann, A. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13793 · Cited by 4 · see citing works
Namiki, T., Nojima, K., Chikazawa, S., Iwamoto, Y., Otsuki, Y., Al‐Busani, H., Miura, K., Kiyokawa, Y., Asakage, T., & Yokozeki, H. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14710 · Cited by 3 · see citing works
Czarnecka, A. M., Kleibert, M., Płachta, I., Rogala, P., Wągrodzki, M., Leszek, P., & Rutkowski, P. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175182 · Cited by 2 · see citing works
Mvandal, S. P., & Mlonganile, W. (2023) · Preprints.org · doi:10.20944/preprints202304.0340.v1 · Cited by 2 · see citing works
Ikejiri, F., Yokomizo, K., & Tamura, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14404 · Cited by 1 · see citing works
Keukeleire, S. D., Vermassen, T., Schoenmakere, G. D., Krüse, V., Vermaelen, K. Y., & Rottey, S. (2019) · Acta Clinica Belgica · doi:10.1080/17843286.2019.1646516 · Cited by 1 · see citing works
Nephrotoxicity in patients receiving immune checkpoint inhibitors
Chuva, T. (2020) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2020.01.047 · Cited by 1 · see citing works
When to Consider Alternatives to Front-Line Immune Therapies in Metastatic Melanoma
Wang, D. Y., & Johnson, D. B. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0005
Self-citationHighlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)
On behalf of the Spanish Melanoma Group (GEM), Soria, A., Manzano, J. L., Berrocal, A., Espinosa, E., Márquez‐Rodas, I., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.37
Prognostic biomarkers, pathogenic studies and treatment of Merkel Cell Carcinoma
Ji, X., Wang, F., Saddozai, U. A. K., Akbar, M. U., Yan, Z., Khattak, S., Guo, X., Xie, L., Zhang, L., Badar, M., et al. (2019) · Journal of Advances in Health · doi:10.3724/sp.j.2640-8686.2019.0120
Insuffisance d’organe (cœur, rein, foie) et traitements du cancer pulmonaire
Pierret, T., Lafitte, C., Boussageon, M., & Duruisseaux, M. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00161-1
Çolak, R., Kapar, C., Gültürk, İ., & Yılmaz, M. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231221230
Qiao, Y., Fu, X., Shukar, S., Ge, W., Yang, W., bin Jiang, R., Dai, X., Chen, H., Zhao, J., Tang, M., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71694
- Authors
- Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., & Johnson, D. B.
- Affiliations
- Vanderbilt-Ingram Cancer Center (US)
- Vanderbilt University (US)
- Roswell Park Comprehensive Cancer Center (US)
- Georgetown Lombardi Comprehensive Cancer Center (US)
- University of Alabama at Birmingham (US)
- Moffitt Cancer Center (US)
- Corresponding author
- Johnson, Douglas B.
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2016-10-18
- Volume
- 4
- Issue
- 1
- Pages
- 60-60
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC5067899
- OpenAlex
- W2522875140
- Cited by
- 75
- References
- 20
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 8 · 2022: 9 · 2021: 8 · 2020: 17 · 2019: 10 · 2018: 8 · 2017: 7
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Cancer Institute (K23CA204726, K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint inhibitors, cardiac dysfunction, renal dysfunction, liver dysfunction, immune-related adverse events, advanced solid tumors, treatment safety, treatment efficacy, progression-free survival, overall survival
- MeSH terms
- Positron Emission Tomography Computed Tomography, Antineoplastic Agents, Immunological, Aged, Aged, 80 and over, Female, Heart, Heart Function Tests, Humans, Kidney, Kidney Function Tests, Liver, Liver Function Tests, Male, Middle Aged, Neoplasm Staging, Neoplasms, Retrospective Studies, Treatment Outcome, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
